Aria’s strategy is to tightly focus its efforts on the development of a novel therapeutic for AD, with the goal of demonstrating proof of principle in humans. Subsequent development and eventual commercialization will be achieved through partnership with an established pharmaceutical or biotechnology company as part of Aria’s exit strategy. Aria will use invested capital in an efficient manner. The core management team will fill the key strategic roles necessary to ensure efficient preclinical, clinical, regulatory, manufacturing, corporate development and finance operations. These positions will be staffed on a consulting relationship basis wherever possible to optimize timing and expense. All development GxP work will be out-sourced to contract research and manufacturing organizations. We have on-going and productive collaborations with a number of academic laboratories that provide support in the areas of chemistry and biology relevant to the AD development program. This research work will be funded through contracts and will be closely managed to ensure it is directed towards the goals of the Company. We do not expect to establish our own laboratory facilities. Aria expects to raise the capital necessary to fund its operations through a variety of channels. In addition to venture capital, we will work to secure funding from organizations such as the Alzheimer’s Association, the Alzheimer’s Foundation, and the National Institutes of Health (NIH) in the form of SBIR and STTR grants.
In collaboration with scientists at NYU School of Medicine, we have screened a number of libraries that included both approved drugs and novel compounds for efficacy and toxicity in various assays relevant to Alzheimer's disease (AD) since 2007. A lead compound ARN-2966 was identified, which showed a strong effect on both Aß production as well as fibrillzation, and Aß oligomerization, and no toxicity at a concentration of 100 µM in human neuroblastoma.
Treatment with ARN-2966 is well tolerated by Alzheimer's transgenic mice at concentrations up to 50 mg/kg, prevents them from developing memory deficit and is associated with reduced Ab load, providing evidence for the activity of ARN-2966 in vivo.
LABORATORIES & OFFICES
Aria's headquarter is located at 295 Washington Avenue in Hamden, CT. Aria will use its research collaborators’ laboratories at NYU Medical School and other commercial and academic institutions to conduct mechanistic research and preclinical efficacy studies under appropriate research agreements. Medicinal chemistry, GLP toxicology, ADME/PK, GMP manufacturing, and GCP clinical trials will be outsourced to CMOs and CROs.